• NMPA approves oral formulation of Akynzeo in China biospectrumasia
    September 25, 2019
    Riccardo Braglia, Helsinn Group Vice Chairman and CEO commented: "Lack of control of CINV is a problem despite the availability of several antiemetics. We are pleased that Akynzeo® that targets two CINV critical pathways in a single dose will help patient
PharmaSources Customer Service